chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Developed a raised rash patch that was a 2 inch patch across around the injection site; Developed a slightly raised rash patch that was itchy around the injection site; Developed a slightly reddish raised rash patch around the injection site; Just had a minor sore shoulder; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Just had a minor sore shoulder), VACCINATION SITE RASH (Developed a raised rash patch that was a 2 inch patch across around the injection site), VACCINATION SITE PRURITUS (Developed a slightly raised rash patch that was itchy around the injection site) and VACCINATION SITE ERYTHEMA (Developed a slightly reddish raised rash patch around the injection site) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 042L20A) for COVID-19 vaccination.     Concurrent medical conditions included Blood pressure. Concomitant products included ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 16-Feb-2021, the patient experienced ARTHRALGIA (Just had a minor sore shoulder). On 24-Feb-2021, the patient experienced VACCINATION SITE RASH (Developed a raised rash patch that was a 2 inch patch across around the injection site), VACCINATION SITE PRURITUS (Developed a slightly raised rash patch that was itchy around the injection site) and VACCINATION SITE ERYTHEMA (Developed a slightly reddish raised rash patch around the injection site). On 27-Feb-2021, VACCINATION SITE RASH (Developed a raised rash patch that was a 2 inch patch across around the injection site), VACCINATION SITE PRURITUS (Developed a slightly raised rash patch that was itchy around the injection site) and VACCINATION SITE ERYTHEMA (Developed a slightly reddish raised rash patch around the injection site) had resolved. At the time of the report, ARTHRALGIA (Just had a minor sore shoulder) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medication list also included blood pressure med combined lisinopril and statin 20 mg. Treatment information was not provided. The patient reported that she refrained from itching, applied lotion and took short showers to relieve the symptoms.
This spontaneous report as received from a pharmacist refers to a 60 year old female patient. Patient had a history of unspecified reactions to sulfa/sulfur medications (unspecified), salicylates (unspecified) and tetracycline (unspecified). On 28-JUL-2014 the patient was vaccinated with ZOSTAVAX, 0.65 ml, subcutaneous in the left arm (strength, dose number, lot number and expiration date were not reported). Concomitant therapies included ZYRTEC. On 29-JUL-2014, 2 days after onset of therapy, the patient experienced rash at injection site. Rash grown larger and covered an area approximately 3 inches from injection site on patient's left arm. No treatment was given for the adverse event. None laboratory diagnostic studies were performed. The patient did not sought medical attention. The outcome of rash was reported as not recovered. The relationship between ZOSTAVAX and the rash was not reported. Additional information has been requested.
Post vax, the pt experienced an unknown adverse event. The pt sought unspecified medical attention.
On 4/13/21 - experienced mild headache and fatigue.  On 4/18/21 - awoke with significant facial rash over bilateral cheeks, nose, chin and forehead.  Rash lasted approximately 10 hours. Completely resolved by the following morning. No other rashes notes.
REACTIONS; This spontaneous report received from a consumer via a company representative concerned multiple patients. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported. On an unspecified date, the patient experienced reactions. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of reactions was not reported. This report was non-serious. This case, from the same reporter is linked to 20220104572 and 20220105368.
Pfizer BioNTech COVID 19 Vaccine EUA Afternoon 1/6/21 temp was 101.6 mild HA feeling flushed and hot, 1/7/21 temp 99.4 moderate HA, chills and muscle aches
Patient did not disclose that he had already gotten a Moderna bivalent booster on 9/23/22. He received a Pfizer bivalent booster 3/6/23. He has no symptoms or side effects.
Vasculitis in fingertips and toes.  The fleshy part of his fingertips got red/purple as well as his big toe.  Has been over a week and has not resovled.
Started to develop a rash a day or two after vaccination. Rash continued to worsen and peaked at about 10 days. Seen in ER and then by myself (Pediatrician). Normal bloodwork. Rash consistent with pityriasis rosea, ? related to the vaccine. Being treated with antihistamines and oral steroids. Rash is itchy, but no signs of trouble breathing.
Had the vaccine on 12/31 at around 9 am. Had pain at the injection site (left upper arm) and muscle aches for 2 days.  On the 6th day (Jan 6) at night, left upper arm started hurting and had on and off chills throughout the night.  on January 7, there was increased pain to left upper arm along with generalized muscle aches and low grade fever constant at 99.9 and 100 throughout the day.  On January 8, decreased pain to left upper arm, no more generalized muscle aches, no fever but easily fatigued.  However, injection site and surrounding area is reddened and warm and tender to touch. Incident reported to Occupational Health as well as had telehealth visit with PCP who recommended cephalexin 500 mg 2x daily for 7 days and to monitor size of redness.
Left arm soreness, Headache 30 mins after, Fever 100.9 T 5am and 9am, monitoring until now
Patient was alert but disoriented, difficulty breathing, speaking in between breathes,  chest tightness, dizziness, and nausea 5 minutes after receiving the Pfizer Covid 19 Vaccine. 911 was called & paramedics arrived at the scene about 10 minutes from onset of patients symptoms. Patient was taken into Paramedics care and transported to the hospital.
Arm sore, after booster; Arm sore, after booster; This is a spontaneous report from a contactable consumer. This consumer (patient's wife) reported for a male patient of an unspecified age received bnt162b2 (BNT162B2 PFIZER-BIONTECH COVID-19 VACCINE, solution for injection Batch/Lot number was not reported) via an unspecified route of administration on 10Nov2021 as dose 3 (booster), single for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. Historical vaccine included first and second dose of bnt162b2 (BNT162B2 PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection Batch/Lot number was not reported) via an unspecified route of administration on an un-specified date as single for COVID-19 immunisation. The patient experienced arm sore, after booster on 10Nov2021.The outcome of events was unknown.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
Redness and heat circumferentially from just below his left shoulder to just above his left elbow/ hand with good perfusion// blistered lesion where he got the shot.
itchy on the arm/Itchiness from above the injection site to the elbow; Area was swollen on the arm; red area from above the injection site to the elbow; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of PRURITUS (itchy on the arm/Itchiness from above the injection site to the elbow), PERIPHERAL SWELLING (Area was swollen on the arm) and VACCINATION SITE ERYTHEMA (red area from above the injection site to the elbow) in a 75-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 023M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 28-Feb-2021, the patient experienced PRURITUS (itchy on the arm/Itchiness from above the injection site to the elbow), PERIPHERAL SWELLING (Area was swollen on the arm) and VACCINATION SITE ERYTHEMA (red area from above the injection site to the elbow). The patient was treated with HYDROCORTISONE (CORTIZONE [HYDROCORTISONE]) at an unspecified dose and frequency. At the time of the report, PRURITUS (itchy on the arm/Itchiness from above the injection site to the elbow), PERIPHERAL SWELLING (Area was swollen on the arm) and VACCINATION SITE ERYTHEMA (red area from above the injection site to the elbow) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.  Treatment information include ice the area down and  cortizone cream.
Arm started to feel sore 5 hours after injection But next evening at 8 pm noticed huge red circular rash and darker smaller inside circle like bulls eye. I took photo.
tremors; This spontaneous case was reported by a consumer and describes the occurrence of TREMOR (tremors) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 051C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 26-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 23-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Jun-2021, the patient experienced TREMOR (tremors). At the time of the report, TREMOR (tremors) outcome was unknown.            Patient started to experienced tremors on the day of second dose, first on the left arm, and then on the right arm  as well, lasting for about 3 hours. Then on the 28-Jun-2021,  she experienced tremors again in both arms lasting around 6 hours, so patient went to the emergency room  where she was administered 1.5 liters of IV saline fluids, and run some blood work  that came back normal. Emergency room  doctors thought patient may have been dehydrated, and ruled out Rhabdomyolysis with the blood work. Then, in 02-July-2021 patient experienced tremors, only on the right arm, and again on 04-Jul-2021, only in the right arm.  This time they were multiple episodes of short duration, around 5 minutes, and less intense.   This case was linked to MOD-2021-246747 (Patient Link).
fever; Chills; diarrhea; sick; weak; This spontaneous case was reported by an other and describes the occurrence of PYREXIA (fever), CHILLS (Chills), DIARRHOEA (diarrhea), ILLNESS (sick) and ASTHENIA (weak) in an 80-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031A21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 22-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 22-Mar-2021, the patient experienced PYREXIA (fever), CHILLS (Chills), DIARRHOEA (diarrhea), ILLNESS (sick) and ASTHENIA (weak). At the time of the report, PYREXIA (fever), CHILLS (Chills), DIARRHOEA (diarrhea), ILLNESS (sick) and ASTHENIA (weak) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       No concomitant medications were provided. No treatment details were provided.   This case was linked to MOD-2021-026683 (Patient Link).
A GOLF BALL SIZE NODE IN ARMPIT OF SAME ARE ARM AS INJECTION SITE. MADE SLEEPING DIFFICULT AND ARE MOVEMENT PAINFUL. ALSO 2 BOILS APPEARED ON FACE, ONE AROUND LEFT EYE AND ANOTHER ON LEFT SIDE OF JAW. INJECTION SITE, EXTREMELY RED SWOLLEN AND DISGUSTING. I HATED GETTING THIS SHOT AND WILL NOT GET IT AGAIN.
Patient developed signs of syncope after Afluria and Adacel administered. Paleness, sweating, nausea, weakness and visual disturbances.
PT RECIEVED TWO IMMUNIZATIONS THIS DATE. ANTHRAX#5 SC IN RIGHT DELTIOD AND TYPHOID SC IN RIGHT TRICEP. PT HAD NO PRIOR HX OF ADVERSE REACTION TO ANTHRAX. PT STATES SIMILAR EVENT OCCURED AFTER LAST FLU AND TYPHOID ADMINISTRATION. PT STATES HE HAD SOB, BLURRED VISION AND "A PRICKLY FEELING ALL OVER". PT GOT REALLY HOT AND BEGIN TO SWEAT.
CHILD RECEIVED WRONG FORMULATION OF THE PFIZER VACCINE FOR AGE. CHILD 11YO AT TIME OF VACCINATION, SHOULD'VE RECEIVED THE PEDIATRIC FORMULATION FOR 5-11YO.
This spontaneous report as received from a registered nurse refers to a patient of unknown age and gender. On 29-DEC-2013 the patient was vaccinated with improperly stored dose of PNEUMOVAX 23 injection 25/0.5 Y (lot # J005068 expiry 18-JAN-2015). No adverse effect reported. No further information was provided. Additional information has been requested.
tongue tingling, feeling of passing out, feels like fast heart rate, pt cleared and left site.
This is a spontaneous report from a contactable consumer. A 79-year-old other ethnic group female patient started to receive PREVNAR13: Lot NumberJ49846, Expiration Date FEB2016, NDC 0005197102) single dose via an unspecified route of administration into the right deltoid on 19NOV2014 at 15:00 hours. Relevant medical history and concomitant medications were not reported. Past event included red cheeks after eating an olive in olive oil. The patient experienced cheeks were red on 19NOV2014 at 17:00 hours and hot, itchy rash to her chest on 19NOV2014 at 22:00 hours. Clinical course was a follows: At 17:00 hours on 19NOV 2014, patient's cheeks were red, but reporter noted that the patient had also eaten an olive in olive oil at this time and the patient had told the reporter that she'd had a similar reaction, red cheeks, after eating an olive in the past. On 19NOV2014 at 22:00 hours, the patient had a hot itchy rash on her chest. On 20NOV2014, patient took BENADRYL 25 mg at 09:00 hours and was seen by the reporter and was found to have flushed, red cheeks, but no rash to her chest. On 18NOV2014, patient got a steroid injection in her left hip at 10:00 hours. Name of steroid was not known by reporter. The reported stated that as of 20NOV2014, the patient was noted to have deep flush on her check bones, the rash was gone, but cheek bones were red. Outcome of the event hot itchy rash to her chest was resolved on an unspecified date and outcome of the event cheeks were red was unknown. Follow-up (14JAN2015): Follow-up attempts completed. No further information expected.
Patient was to receive the Moderna BIVALENT booster but received Moderna NON-BIVALENT booster.
This spontaneous report was received from a registered nurse, concerning unspecified number of patients of unknown age and gender. There were no concurrent conditions, medical history, drug reactions or allergies or concomitant medications reported. On unspecified dates, the patients were vaccinated with improperly stored dose of PEDVAXHIB (dose, frequency and route were not reported) lot # M025193 with expiration date of 21-MAR-2019 and lot # M036612 with expiration date of 19-MAY-2019, for prophylaxis. The temperature of the PEDVAXHIB was between 0 °C and 1 °C (1 °C) for a time frame of 30 minutes; below -1 °C (-1°C) for a time frame of 30 minutes. No previous temperature excursion occurred and no data logger was involved. No adverse effects were reported. This is one of three reports received from the same source. Additional information has been requested. Sender's Comments: US-009507513-1704USA015181: US-009507513-1705USA000411.
Five days post vax, 06/23, this pt experienced fever, not eating. Fevers continued for days. Broke out in rash and had no activity. By 07/1/00, he was not responding to anything. Given Motrin during this time. He was taken to the ER on the 1st where he was admitted and tests were conducted. Release on 07/03. Diagnosed with difficulty breathing and croup. Per F/U 9/17/01: Pt developed respiratory distress at home. Prescribed Prelone 1 tsp BID.
Pain and Stiffness in left shoulder immediately, increasing to point of preventing/slowing movement the following day, especially when exercising. Nausea, fatigue, and minor headache the following after noon.
Pain at injection site; Sore arm; This is a spontaneous report from a contactable consumer or other non-health care professional.  A 55-year-old male received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Batch/Lot number was EN6198) via unspecified route of administration, administered in arm left on 28Feb2021 at 14:45 (age at the time of vaccination was 55-year-old) as a dose 1, single dose for COVID-19 immunization. The patient's relevant medical history included high blood pressure, high cholesterol, seasonal allergies and transient ischemic attack (13 years ago) from an unspecified date. The patient's concomitant medications include Folic Acid 1 mg, Aspirin 81 (ACETYLSALICYLIC ACID), Vitamin D3, Hydrochlorothiazide 25 mg, Levocetirizine Dihydrochloride 5mg, Fenofibrate 145 mg and Vitamin C (ASCORBIC ACID) and Zinc Chloride taken for an unspecified indication. On 28Feb2021 (at 08:00), the patient experienced Pain at injection site and Sore arm. The patient received Acetaminophen as treatment medication for adverse events. The patient was made aware in the late evening of Sunday, 28Feb2021 and had a personal situation on Monday, 01Mar2021, so was not able to report on 01Mar2021. He reported as soon as was able to on Tuesday, 02Mar2021. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, patient was diagnosed with COVID-19. Since the vaccination, patient has been not tested for COVID-19. The clinical outcome of events was recovering.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Pt received vaccine, about 5 mins later he stated he was not feeling well, but could not articulate symptoms. He was breathing ok, but was in a state of panic. He requested we call 911, which we did immediately, and gave him an ice pack. EMTs arrived and he refused transport. He called his mother, who came and got him. EMTs waited with him until she arrived.
Felt fine after first dose on 4/15 just my left arm was a little sore the next day 4/16. Soreness went away after two days 4/18. Eight days after the initial does on 4/23 my injection site became red, hot to the touch, swollen, and painful. 4/24 the redness and swelling was less. By 4/25 my injection site was fine.
his arm is sore, every time he raises his hand he feels his arm is sore; Muscles sore/Soreness near injection site muscles; he makes a quick motion, he feels the soreness too. It is in the muscle area of the injection site; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (his arm is sore, every time he raises his hand he feels his arm is sore), MYALGIA (Muscles sore/Soreness near injection site muscles) and VACCINATION SITE PAIN (he makes a quick motion, he feels the soreness too. It is in the muscle area of the injection site) in a 44-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 017F21A, 024M20A and 040A21A) for COVID-19 vaccination.     No Medical History information was reported.   On 25-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 23-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PAIN IN EXTREMITY (his arm is sore, every time he raises his hand he feels his arm is sore), MYALGIA (Muscles sore/Soreness near injection site muscles) and VACCINATION SITE PAIN (he makes a quick motion, he feels the soreness too. It is in the muscle area of the injection site). At the time of the report, PAIN IN EXTREMITY (his arm is sore, every time he raises his hand he feels his arm is sore), MYALGIA (Muscles sore/Soreness near injection site muscles) and VACCINATION SITE PAIN (he makes a quick motion, he feels the soreness too. It is in the muscle area of the injection site) had not resolved.            No relevant concomitant medications were reported.  No treatment information was provided.   This case was linked to MOD-2021-424465, MOD-2021-424521 (Patient Link).
Excema appears all over body-extreme itching. Not responded to OTC or Rx creams, antihistamines or otal steroids.
After rec. vaccine at 11:35am, extreme fatigue noted from approx 1:00pm- 9:00pm. At approx 4:30-6:00pm area around left eye a small flashing eura with color outside which did effect vision slightly. Stopped approx 6:00pm.
This is a spontaneous report from a contactable nurse via a Pfizer sales representative. A female patient of an unspecified age, race and ethnicity received a single dose of PREVNAR 13 via an unspecified route of administration in the left arm on an unspecified date for immunization.  The patient medical history and concomitant medications were not reported. After the vaccination on an unspecified date the patient experienced atrophy of left arm. The patient was planning plastic surgery due to the event. Outcome was unknown. Sender's Comments: The information available in this report is limited and does not allow a medically meaningful assessment of the case. In particular, the following relevant information is not available: date of vaccination and onset date of the event. This case will be reassessed when additional information becomes available. The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees and Investigators, as appropriate.
A report has been received from a Physician concerning a subject of  unknown gender, who had been receiving FLUMIST QUADRIVALENT. FLUMIST QUADRIVALENT started on an unknown date. Physician had reported that they had inadvertently administered only 1/2 the dose of FLUMIST QUADRIVALENT in one nostril to 199-200 people. The outcome of the event of administered 1/2 the dose of FLUMIST QUADRIVALENT to 199-200 people is unknown. The report was considered to be non-serious.